Tumor virology explores the role of viruses in cancer development and progression. Several human viruses including human papillomavirus (HPV), Epstein–Barr virus (EBV), hepatitis B and C viruses (HBV, HCV), and human T-cell leukemia virus (HTLV-1) are known to be oncogenic, contributing to approximately 15–20% of global cancer cases. These oncogenic viruses can integrate into host genomes, alter cellular signaling pathways, evade immune detection, and induce chronic inflammation, all of which promote malignant transformation. Tumor virology also investigates viral latency, reactivation, and the mechanisms by which viruses disrupt tumor suppressor genes or activate oncogenes.
Importantly, this field has contributed to major breakthroughs in cancer prevention, including the development of vaccines such as the HPV and HBV vaccines, which have significantly reduced the incidence of cervical and liver cancers. Oncolytic viruses, which selectively infect and kill cancer cells, represent another promising therapeutic avenue.
We welcome research on viral oncogenesis, virus-host interactions, and the development of virus-based therapies and vaccines. We are particularly interested in studies that bridge virology and immuno-oncology, offering insights into novel strategies for cancer prevention and treatment rooted in our understanding of viral biology.